key: cord-1000255-hxyn84jt
authors: Zhou, Yue; Yang, Qing; Chi, Jingwei; Dong, Bingzi; Lv, Wenshan; Shen, Liyan; Wang, Yangang
title: Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis
date: 2020-07-25
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.029
sha: 05b91d9f5042f216ee050ea7ff8d2482b794dd00
doc_id: 1000255
cord_uid: hxyn84jt

Abstract Objectives Existing findings regarding the relationship between comorbidities and Covid-19 severity is inconsistent and insufficient. The present study aimed to evaluate the association between different comorbidities and the severity of Covid-19. Methods PubMed, EMBASE, and the Cochrane Library were searched to identify studies reporting on the rate of comorbidities in Covid-19 patients with severe/fatal outcomes. Subgroup analyses were conducted according to disease severity, and the country of residence. Odds ratio (OR) with 95% confidence intervals (CI) were pooled using random-effects models. Results A total of 34 eligible studies were identified. In patients with severe/fatal Covid-19, the most prevalent chronic comorbidity was obesity (42%, 95CI 34-49%) and hypertension (40%, 95%CI 35-45%), followed by diabetes (17%, 95%CI 15-20%), cardiovascular disease (13%, 95%CI 11-15%), respiratory disease (8%, 95%CI 6-10%), cerebrovascular disease (6%, 95%CI 4-8%), malignancy (4%, 95% CI 3-6%), kidney disease (3%, 95%CI 2-4%), and liver disease (2%, 95%CI 1-3%). In order of the prediction, the pooled ORs of the chronic respiratory disease, hypertension, cardiovascular disease, kidney disease, cerebrovascular disease, malignancy, diabetes, and obesity in patients with severe or fatal Covid-19 were (OR 3.56, 95%CI 2.87-4.41), (OR 3.17, 95%CI 2.46-4.08), (OR 3.13, 95%CI 2.65-3.70), (OR 3.02, 95%CI 2.23-4.08), (OR 2.74, 95%CI 1.59-4.74), (OR 2.73, 95%CI 1.73-4.21), (OR 2.63, 95%CI 2.08-3.33), and (OR 1.72, 95%CI 1.04-2.85), respectively, compared with patients with non-severe/fatal Covid-19. No correlation was observed between liver disease and Covid-19 aggravation (OR 1.54, 95%CI 0.95-2.49). Conclusions Chronic comorbidities, including obesity, hypertension, diabetes, cardia-cerebrovascular disease, respiratory disease, kidney disease, and malignancy, are clinical risk factors of severe or fatal outcomes associated with Covid-19, with obesity being the most prevalent, and respiratory disease being the most strongly predictive. Knowledge of these risk factors can help clinicians better identify and guide the high-risk populations.

The outbreak of the coronavirus disease 2019 , which caused by a novel enveloped RNA beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , has become a public health emergency of international concern. The manifestations of Covid-19 pneumonia run the spectrum from asymptomatic disease to severe acute respiratory infection (Chen Nanshan et al., 2020 , Deng and Peng, 2020 , Wang Dawei et al., 2020 , and the recognized human-to-human transmission significantly increases the risk of much wider spread of the disease (Li Qun et al., 2020 , Phan et al., 2020 , Rothe et al., 2020 . As of June 11, 2020, 7 273 958 confirmed Covid-19 cases and 413 372 deaths were reported globally. At present, the number of Covid-19 cases is still increasing around the world, and there are increasing global concerns about this outbreak (Wang Chen et al., 2020) . Given this, the identification of clinical risk factors of poor outcomes associated with Covid-9 are desperately needed to distinguish which populations are at enhanced risk, thus needing more aggressive management to prevent its severe or fatal outcomes.

A number of literature reports have documented the escalated risks of poorer clinical outcomes in patients infected with avian influenza (Martínez et al., 2019 , Mauskopf et al., 2013 , Placzek and Madoff, 2014 , SARS-CoV (Booth et al., 2003) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) (Alanazi et al., 2020 , Alqahtani et al., 2018 , Badawi Alaa and Ryoo Seung Gwan, 2016 , Matsuyama et al., 2016 , Yang et al., 2017 , which showed that the comorbidities including diabetes mellitus (DM), hypertension, cardiovascular disease (CVD), chronic respiratory diseases, chronic kidney diseases (CKD), and malignancy are significantly associated with poor prognosis or even death. Some clinical risk factors of poor prognosis associated with Covid-19 have also been J o u r n a l P r e -p r o o f reported, including older age, male sex, and the presence of comorbidities Peng, 2020, Yang Xiaobo et al., 2020) , with hypertension being the most common, followed by DM and CVD (Huang Chaolin et al., 2020 , Wang Dawei et al., 2020 . Given the virtually unstoppable global trend of SARS-CoV-2, together with the high prevalence of comorbidities worldwide, the combination of these two conditions will pose greater clinical, societal, and economic burdens to humanity (Emanuel et al., 2020) .

To date, a few meta-analyses (Borges do Nascimento et al., 2020 , Lippi et al., 2020 have been published regarding the prevalence of comorbidities in Covid-19 infection, all of which indicated that hypertension and CVD are risk factors for Covid-19 patients progressing to severe or critical cases. However, with the limited data set comparing the proportion of comorbidities between severe and non-severe cases, there are uncertainties or controversies on the relationship between particular comorbidities, including DM, obesity, CKD, liver disease and malignancy, and the Covid-19 severity. For instance, the metaanalysis conducted by Yang et al. and Li et al. showed no significant association between DM and the severe outcomes associated with Covid-19, and the meta-analysis conducted by Wang et al. showed no correlation between CKD, liver disease or malignancy, and the aggravation of Covid-19 patients. To date, no meta-analysis has been conducted to evaluated the relationship between obesity and the Covid-19 severity. Besides, the judgment criteria for severe and non-severe disease were uniform in those meta-analysis, which got mixed up with severe clinical symptoms, ICU admission and mortality. With the lack of the separate analyses according to disease severity, whether and how much the comorbidities impact on the risk of ICU admission, or mortality has not been clearly established. In addition, studies included J o u r n a l P r e -p r o o f in those meta-analyses were confined to China, mainly in Wuhan, making their conclusions some unrepresentative.

With the epidemiologic and clinical features of Covid-19 cases increasingly reported around the world, we aim to integrate the recent advances and present an up-date meta-analysis of the relationships between comorbidities and the severe or fatal outcomes associated with Covid-19.

We performed this meta-analysis based on a prespecified protocol, and report our methods and results according to the PRISMA guidelines (Stewart et al., 2015) .

A systematic search was conducted on articles published in PubMed, EMBASE, and the Cochrane Library from inception to April 25, 2020. According to the indices of the various databases, we use the search term "2019 novel coronavirus", "COVID-19", "Novel Coronavirus Pneumonia", "2019-Cnov", "SARS-CoV-2", "Betacoronavirus", "bat coronavirus", "comorbidities", "pre-existing disease", "underlying disease", "clinical characteristics", "epidemiological", "severe", "critical", "Intensive care unit", "ICU", "death", "fatality", and "mortality" in English. To identify missing studies, we had checked the reference list for each selected paper. The detailed search strategy is available in supplemental 

Two independent authors (Y. Zhou, Q. Yang) screened the search results and selected studies in accordance with the inclusion and exclusion criteria. Two authors (JW. Chi, BZ. Dong) used predefined forms to extract data from each included study: trial characteristics (first author, publication year, study design, sample size, definition of severity), patients' baseline [age (from reported mean or median age), the prevalence of comorbidities including obesity (body mass index > 30 kg/m 2 ), hypertension, DM (both type I and type II, if separately mentioned), CVD, cerebrovascular diseases, chronic respiratory disease, CKD, liver disease, and malignancy]. The prevalence of comorbidities was measured by extracting the proportion of coexisting medical conditions from confirmed Covid-19 cases with or without severe manifestations, ICU or non-ICU cases, survivors or non-survivors. In articles including the same or duplicated patients, we only included the most complete data to avoid overlap. If any overlapping was suspected, corresponding authors were contacted to clarify the discrepancy. Any resulting disagreements were resolved by discussion with a third author (W. Lv). Disagreements between authors were resolved with consensus.

Pooled analysis was performed to estimate the odds ratio (OR) and 95% confidence interval (95% CI) of comorbidities in Covid-19 patients with or without severe clinical symptoms, ICU or non-ICU patients, survivors or non-survivors. Considering the heterogeneity within and between studies, a random effect model was used to estimating the average effect and its precision, which would give a more conservative estimate of the 95% CI. A P-value < 0.05 for any test or model was considered statistically significant. The degree of between-study variability attributable to heterogeneity beyond chance was calculated using the I 2 statistic and Q statistic (Higgins and Thompson, 2002) .

Outcomes with I 2 levels from 0% to 40% were considered minimally heterogeneous, while I 2 > 50% was considered an indication of statistically significant heterogeneity among included studies.

We further conducted perspective subgroup analyses according to the severity of disease (severe disease based on clinical symptom, ICU admission, or death), and country of residence, to address the clinical heterogeneity of included studies. Forest plots were used for graphic representation of the data. Funnel plots and Egger test were used for assessing publication bias. The meta-analyses were performed by the STATA software, version 12.0 (Stata Corp, TX, USA).

The combined search of the PubMed, EMBASE, and the Cochrane Library databases identified 3144 citations, of which a total of 34 articles(2020a, 2020b, 2020c, Barrasa et al., 2020 , Cai et al., 2020 , Chen Tao et al., 2020 , Chen Xiaohua et al., 2020 , Deng et al., 2020 , Gao et al., Goyal et al., 2020 , Grasselli et al., 2020 , Guan Wei-jie et al., 2020 , Huang Chaolin et al., 2020 , Li K. et al., 2020 , McLaughlin et al., 2014 , Piva et al., 2020 , Qin et al., 2020 , Shen et al., 2020 , Simonnet et al., Wan et al., Wang D. et al., 2020 , Wang Zhongliang et al., 2020 J o u r n a l P r e -p r o o f Chaomin et al., 2020 , Yang F. et al., 2020 , Yao et al., 2020 , Young et al., 2020 , Zheng S. et al., 2020 met all inclusion criteria. After removal of duplicates, the title and abstracts of search results were screened for relevance. The full texts of remaining results were independently assessed in duplicate by 2 authors (JW. Chi and WS. Lv) for inclusion based on predetermined criteria. The process used to select studies for the meta-analysis is available in Figure 1 .

Characteristics of the included studies were mentioned in supplementary Table 1 . Of these, 30 studies were classified as retrospective cohort studies (Barrasa et al., 2020 , Cai et al., 2020 , Chen Tao et al., 2020 , Chen Xiaohua et al., 2020 , Deng et al., 2020 , Gao et al., Guan Wei-jie et al., 2020 , Li K. et al., 2020 , Piva et al., 2020 , Qin et al., 2020 , Shen et al., 2020 , Simonnet et al., Wu Chaomin et al., 2020 , Yang F. et al., 2020 , Yao et al., 2020 , Zheng S. et al., 2020 , 7 as retrospective case series (Goyal et al., 2020 , Grasselli et al., 2020 , Wan et al., Wang D. et al., 2020 , Wang Zhongliang et al., 2020 , Young et al., 2020 , and 4 as surveillance studies (studies extracting data from a database of cases, systematically gathering epidemiological data, as coordinated by a country or WHO) (2020a ( , 2020b ( , 2020c ( , McLaughlin et al., 2014 , with a total of 16 110 patients from 9 different countries including China, the USA, UK, Italy, French, Spain, Australia, Singapore and Korea. The published prevalence of comorbidities including obesity, hypertension, DM, CVD, cerebrovascular diseases, chronic respiratory disease, CKD, chronic liver disease, and malignancy. In particular, 18 studies (Cai et al., 2020 , Chen Xiaohua et al., 2020 , Gao et al., Goyal et al., 2020 , Guan Wei-jie et al., 2020 , Li K. et al., 2020 , Qin et al., 2020 J o u r n a l P r e -p r o o f Zhongliang et al., 2020 , Wu Chaomin et al., 2020 , Young et al., 2020 , Zheng S. et al., 2020 compared the rate of comorbidities in severe vs. non-severe cases based on clinical symptoms with a sample of 4001 patients, 1272 (31.8%) of whom were classified as having developed severe disease. 4 studies(2020c, , Shen et al., 2020 , Wang D. et al., 2020 compared the rate of comorbidities in ICU vs. non-ICU cases with a sample of 6652 patients, 1138 (17.1%) of whom were classified as admitting to ICU. 5 studies (Chen Tao et al., 2020 , Deng et al., 2020 , McLaughlin et al., 2014 , Yao et al., 2020 compared the rate of comorbidities in survivors vs. non-survivors with a sample of 3436 patients, 1624 (47.3%) of whom were fatal cases. Another 7 studies(2020a, 2020b, Barrasa et al., 2020 , Grasselli et al., 2020 , Piva et al., 2020 , Yang F. et al., 2020 only reported the proportion of comorbidities in severe/ICU/fatal populations, without comparing to their non-severe/ICU/fatal counterparts.

As shown in Figure 2 , in Covid-19 patients with severe or fatal outcomes, the most prevalent comorbidity was obesity (42%, 95 CI 34-49%) and hypertension (40%, 95% CI 35-45%), followed by DM (17%, 95% CI 15-20%), CVD (13%, 95% CI 11-15%), respiratory disease (8%, 95% CI 6-10%), cerebrovascular disease (6%, 95% CI 4-8%), malignancy (4%, 95% CI 3-6%) and CKD (3%, 95% CI 2-4%), and the least prevalent comorbidity was liver disease (2%, 95% CI 1-3%). Subgroup analyses according to country of residence of the study participants further showed the ethnic differences in the prevalence of comorbidities among patients with severe or fatal Covid-19.

The risk of comorbidities in severe/ICU/fatal patients compared to non-severe/ICU/fatal patients J o u r n a l P r e -p r o o f

We then compared the difference of the prevalence of comorbidities between severe and non-severe patients, ICU and non-ICU patients, survivors and non-survivors, stratifying the estimates by disease severity (Table 1; Figure 3 ) and country of residence (Figure 4) . The pooled summary estimates from included studies indicated that, comorbidities including obesity, hypertension, DM, cardia-cerebrovascular disease, respiratory disease, CKD and malignancy, are clinical risk factors of severe or fatal Covid-19.

In particular, although respiratory disease was relatively uncommon among the comorbidities, it was by far the most strongly predictive comorbidity for the composite adverse outcomes associated with Covid-19, with ORs of 4.17 (95% CI 2.67-6.50), 3.32 (95% CI 2.55-4.32) and 4.06 (95% CI 1.77-9.31), respectively, for the severe clinical manifestations, ICU admission, and death (Supplementary Figure 1F) . In contrast, despite being the most common comorbidity, obesity was not a strong prediction for Covid-19 severity. Subgroup analysis showed that obesity is significantly related to the increased risk of mechanical ventilation during the ICU admission (OR 2.29, 95% CI 1.22-4.29), but not associated with excess mortality (OR 1.15, 95% CI 0.98-1.34; Supplementary Figure 1A ). Additionally, patients coexisting hypertension were 2.75 (95% CI 2.08-3.64), 5.34 (95% CI 1.52-18.71), and 3.45 (95% CI 2.23-5.34) times, respectively, more likely to develop into severe manifestations, ICU admission and death, compared to those without hypertension (Supplementary Figure 1B) . Patients with diabetes were 2.73 (95% CI 1.95-3.82), 2.98 (95% CI 1.49-5.98) and 2.08 (95% CI 1.38-3.15) times more likely to progress into severe manifestations, ICU admission and death, compared to non-diabetic patients (Supplementary Figure 1C) . Meanwhile, having CVD was more likely to progress into severe manifestations, ICU admission and death, compared with those without CVD, with ORs of 3.05 (95% CI 2.26-4.11), 2.97 (95% CI 2.40-3.68) and 5.92 (95% CI Among the comorbidities, liver disease was the only comorbidity that was insignificantly associated with the severe or fatal Covid-19 (OR 1.54, 95% CI 0.95-2.49; Supplementary Figure 1H ). Besides, subgroup analyses according to the country of residence further showed the ethnic differences in the association between comorbidities and the severe or fatal Covid-19 ( Figure 4) .

The funnel plot did not reveal obvious asymmetry, and the Egger's test didn't show any significant publication bias (Egger's test: P > 0.05), indicating the results are relatively robust. The funnel plot is presented in Supplementary Figure 2A -H.

The present study systematically evaluated the association between chronic comorbidities and the poor clinical outcomes associated with Covid-19, with a large sample size and extensive coverage of the regions around the world. Our findings showed that, among patients with severe or fatal

Covid-19, the most prevalent comorbidity was obesity (42%) and hypertension (40%), followed by diabetes (17%), CVD (13%), respiratory disease (8%), cerebrovascular disease (6%), malignancy (4%), CKD (3%) and liver disease (2%). Comorbid respiratory disease was identified as the strongest risk factor for Covid-19 severity, with a nearly 3.6-fold higher risk of developing poor outcomes, followed by hypertension, CVD, CKD, cerebrovascular disease, malignancy, diabetes and obesity. The meta-analysis did not present a significant correlation between liver disease and Covid-19 aggravation. The knowledge of these factors can help clinicians better identify the highrisk populations associated with Covid-19, and provide more specific approaches to prevent severe or fatal outcomes. Similar comorbidity effects have been noted in other severe acute respiratory outbreaks, such as influenza illness (Mertz et al., 2013) , MERS-CoV (Badawi A. and Ryoo S. G., 2016) and SARS-CoV infections (Chan et al., 2003) . However, the strength of association between particular comorbidities and the prognosis of these respiratory disease was less consistent when compared with the literature reports (Booth et al., 2003 , Garbati et al., 2016 , Matsuyama et al., 2016 , Mertz et al., 2013 . Recent pathology and virology studies indicated that, compared with influenza virus and respiratory syncytial virus, SARS-CoV-2 could lead to a muted response that lacks robust induction of a subset of cytokines, including the Type I and Type III interferons, and a numerous chemokines (Blanco-Melo et al., 2020) . Moreover, the growth rate of Covid-19 is much higher than that of SARS and MERS, determining its special prevalence in the early stage (Liang, 2020) . To date, a few meta-analyses (Borges do Nascimento et al., 2020 , Lippi et al., 2020 have been published to report the prevalence of comorbidities in Covid-19 infection, all of which indicated that hypertension and CVD are risk factors for Covid-J o u r n a l P r e -p r o o f comorbidities between severe and non-severe cases, there were inconsistent or lacking conclusions regarding the association between obesity, diabetes, CKD, malignancy, and the serious adverse outcomes associated with Covid-19. In addition, literatures included in those meta-analyses were confined to China, mainly in Wuhan, and the judgment criteria for severe and non-severe disease were uniform, making their conclusions confusing and unconvincing.

This study, with a large sample size and extensive coverage of the regions worldwide, provided further evidence to the relationship between different comorbidities and the Covid-19 severity. The findings reported here are in keeping with current knowledge that circulatory and endocrine diseases (including hypertension, cardiovascular diseases, obesity and diabetes) is the most common category of comorbidity (Guan W. J. et al., 2020) . Meanwhile, our findings added new evidence that obesity, with a proportion of up to 42%, was the most prevalent comorbidity among patients with severe or fatal Covid-19. Of note, we found obesity led to a higher risk of mechanical ventilation, than of death, among patients admitted to ICU. Actually, obesity has been considered as a risk factor for increased morbidity among critically ill patients, but not consistent with mortality (Aldawood et al., 2006 , Fezeu et al., 2011 , Goulenok et al., 2004 , Peake et al., 2006 , Sakr et al., 2008 . Specially, some researches have indicated that a low BMI, but not a high BMI, was a significant and independent predictor of mortality (Galanos et al., 1997, Tremblay and Bandi, 2003) . In contrast, despite being uncommon in the study population, chronic respiratory disease was identified as the strongest risk factor for severe or fatal Covid-19. Except chronic liver disease, patients with any comorbidity (e.g. obesity, hypertension, diabetes, cardia-cerebrovascular disease, respiratory disease, CKD and malignancy) yielded poorer clinical outcomes associated with Covid-19. This finding is different from previous results of the meta-analyses conducted by Yang et al. and Li et al. that there were insignificant associations between diabetes and severe Covid-19, and the meta-analysis conducted by Wang et al. ) that there were no correlation between CKD, malignancy, and the Covid-19 patients' aggravation.

Anyhow, our findings suggested that all of above-mentioned comorbidities should be taken into account when predicting the prognosis in patients with Covid-19, and better protection should be given to the high-risk patients upon diagnosis.

Chronic comorbidities share several standard features with infectious disorders, such as the prolonged pro-inflammatory state and the dysfunction of innate and adaptive immunity (Brownlee, 2001 , Hameed et al., 2015 , which may be the key drivers of the worse clinical outcomes in patients infected with SARS-CoV-2. Specially, angiotensin-converting enzyme 2 (ACE2), which was highly expressed in the lung and heart tissues (Turner et al., 2004) , has been identified as an important functional receptor for SARS-CoV-2 invasion (Wu Fan et al., 2020) . In patients with obesity, diabetes or CVD, the expression of ACE2 has been found up-regulated, thus increasing the susceptibility to SARS-CoV-2 infection and the risk of disease aggravation (Jia et al., 2020 , Roca-Ho et al., 2017 , Zheng and Ma, 2020 . In addition, pulmonary physiological abnormalities (Ashburn et al., 2010 , Kida et al., 1983 and microangiopathy (Teeter and Riese, 2008, Williams et al., 1984) , increased viral diversity and titers (Domingo, 1997, Lauring and Andino, 2010) , and prolonged viral shed (Ryan and Caplice, 2020) associated with obesity and diabetes, might also escalate the risk of disease aggravation. On the other hand, Covid-19 infection could in turn worsen pre-existing comorbidities, or even cause new-onset endocrine and metabolic disorders, which further formed a vicious circle. Researchers have observed that the insulin dose increased and blood glucose became difficult to control after diabetic patients were infected with SARS-CoV-2 (Guo et al., 2020, Zhou and , suggesting the virus has an impact on glucose metabolism. Actually, it has been proposed that SARS-CoV-2 could bind to ACE2 in liver and islet, with a potential role in the development of insulin resistance and impaired insulin secretion, further causing acute diabetes or worsen diabetes prognosis , Yang et al., 2010 . Pre-existing CVDs also become unstable, with the increased incidence of acute coronary syndromes, heart failure and arrhythmias in the setting of SARS-CoV-2 infection, probably resulting from the imbalance between the increased metabolic demand and reduced cardiac reserve (Kochi et al., 2020) , concurrent with an accentuated inflammatory response and myocardial damage (Wang D. et al., 2020) . In addition to the lung and heart tissues, the expression of ACE2 has also been found in kidneys, testes, bladders, livers, stomachs, intestinal epitheliums and the vascular endotheliums (Hamming et al., 2004 , Yang et al., 2010 , providing a mechanism for the multi-organ dysfunction that can be seen with SARS-CoV-2 infection.

Our findings have therefore added to the existing literature the spectrum of comorbidities in patients with Covid-19, based on the larger sample sizes and representativeness of the whole patient population around the world. However, we still acknowledge several limitations of this study. First, heterogeneity existed among the eligible studies in some meta-analyses, which was probably the result of differences in the baseline characteristics of participants, and large variation among studies in the sample sizes. For this reason, we used a random effects model for all analyses and performed subgroup analyses to find sources of heterogeneity. Second, as an inherent limitation of all metaanalyses of observational data, we cannot exclude the possibility that the association is affected by some confounding factors, such as age, body mass index, and baseline respiratory function. Taking into account these confounding risk factors would only have been relevant to the extent that comorbidities was considered as a causative factor. Next, although we divided disease severity based on clinical symptoms, ICU care and death, the included studies still varied in their differentiation of patients' disease severity in clinical definition, with classifications of "mild, moderate, severe, and critical", "ordinary and severe/critical", "common and severe", and "non-severe and severe" disease.

In conclusion, chronic comorbidities including obesity, hypertension, diabetes, cardiacerebrovascular disease, respiratory disease, kidney disease, and malignancy, are clinical risk factors of severe or fatal outcomes associated with Covid-19, with obesity being the most prevalent, and respiratory disease being the most strongly predictive. Knowledge of these risk factors can better identify the high-risk Covid-19 patients, and thus allow a more specific approach to prevent severe or fatal outcomes. Further investigations are needed to clarify the pathophysiologic explanations underlying the association found in our meta-analysis. Shen edited the report and all authors contributed to revision of the report. All authors reviewed the manuscript, approved the final draft and agreed to submit it for publication. ICU, intensive care unit; OR (95% CI), odds ratio and 95% confidence interval.

The association between chronic comorbidities and the severe or fatal Covid-19 according to country of residence. OR (95% CI), odds ratio and 95% confidence interval. Abbreviations: CI, confidence intervals; ICU, intensive care unit; OR, odds ratio.

Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea. Osong public health and research perspectives 2020a

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Diabetes Mellitus, Hypertension, and Death among 32 Patients with MERS-CoV Infection, Saudi Arabia

Association of obesity with increased mortality in the critically ill patient

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

Pulmonary system and obesity

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

SARS-Cov-2 in Spanish Intensive Care: Early Experience with 15-day Survival In Vitoria

SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Biochemistry and molecular cell biology of diabetic complications

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Short term outcome and risk factors

Epidemiological and clinical 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Characteristics of and Public Health Responses to the Coronavirus Disease

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

RNA virus evolution, population dynamics, and nutritional status

Fair Allocation of Scarce Medical Resources in the Time of Covid-19

COVID-19 with Different Severity: A Multicenter Study of Clinical Features

Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis

Relationship of body mass index to subsequent mortality among seriously ill hospitalized patients. SUPPORT Investigators. The Study to Understand Prognoses and Preferences for Outcome and Risks of Treatments

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes

Influence of Overweight on ICU Mortality: A Prospective Study

Clinical Characteristics of Covid-19 in

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical Characteristics of Coronavirus Disease 2019 in China

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. The European respiratory

Diabetes is a risk factor for the progression and prognosis of COVID-19

Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Quantifying heterogeneity in a meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Two Things about COVID-19 Might Need Attention

Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats

Cardiac and arrhythmic complications in Covid-19 patients

Quasispecies theory and the behavior of RNA viruses

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Mathematical model of infection kinetics and its analysis for COVID-19

Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Polish archives of internal medicine

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype

Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis

The burden of influenza complications in different high-risk groups: a targeted literature review

T-Cell Profile in Adipose Tissue Is Associated With Insulin Resistance and Systemic Inflammation in Humans

Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis

The effect of obesity on 12-month survival following admission to intensive care: a prospective study

Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam

Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in

Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine Amplification in COVID-19

Obesity is associated with increased morbidity but not mortality in critically ill patients

Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement

Cross-Sectional and Prospective Study of Lung Function in Adults With Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Response to Yeh et al

Impact of body mass index on outcomes following critical care

ACE2: from vasopeptidase to SARS virus receptor

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

A novel coronavirus outbreak of global health concern

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Pancreatic injury patterns in patients with COVID-19 pneumonia

Clinical Features of 69 Cases with Coronavirus Disease

Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

A new coronavirus associated with human respiratory disease in China

Analysis of 92 deceased patients with COVID-19

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome

Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Polish archives of internal medicine

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

COVID-19 and the cardiovascular system

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diabetes patients with COVID-19 need better blood glucose management in Wuhan